All the news Showing 3 of 33 articles from: EASL 2015Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Cirrhosis Sofosbuvir/ledipasvir plus ribavirin shows high cure rate for hepatitis C patients with advanced liver disease Liz Highleyman / 24 April 2015 An oral regimen of sofosbuvir/ledipasvir (Harvoni) and ribavirin taken for 12 or 24 weeks produced sustained virological response rates of 85-88% for people with genotype 1 or 4 hepatitis C virus ... Cirrhosis Merck HCV combination achieves 90% cure in advanced cirrhosis Keith Alcorn / 24 April 2015 A 12-week course of treatment with two direct-acting antivirals in development by Merck cured hepatitis C infection in 90% of people with very advanced cirrhosis and at imminent risk of liver failure, ... Treatment for previous non-responders & relapsers Merck HCV combination effective after failure of first generation of direct-acting antivirals Keith Alcorn / 24 April 2015 A 12-week course of treatment with two direct-acting antivirals in development by Merck plus ribavirin cured 95% of people with hepatitis C who had experienced failure of a previous treatment combination containing a ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive